Breaking: Trump administration declines to expand Medicare coverage for obesity drugs

BREAKING NEWS

Trump administration declines to expand Medicare coverage for obesity drugs

By Bob Herman, Elaine Chen, and John Wilkerson

Rick Berke / STAT

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed Medicare to cover blockbuster weight loss drugs.

Introduced by President Biden at the end of his term, the proposal would have expanded coverage of the treatments for weight loss purposes to all people with obesity in Medicare and Medicaid programs. The rule would have brought in tens of billions of dollars in new sales for drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Are you affected by the HHS cuts and restructuring?

We are eager to hear from readers who have been impacted by the mass layoffs and restructuring at the agency and others under its umbrella. Share your experience with STAT's reporters in this form. We will not share your name or story without your permission.

In Case You Missed It

Five NIH institute directors and numerous lab heads ousted in unprecedented shake-up

By Megan Molteni, Jonathan Wosen, and Jason Mast

A running list of senior FDA officials who have left the agency

By Lizzy Lawrence and J. Emory Parker

Trump administration orders NIH to eliminate $2.6 billion in federal contracts

By Megan Molteni

Federal advisory panel on ethical, legal issues in human health research disbanded

By Megan Molteni and Ed Silverman

Get 50% off an annual STAT+ subscription

STAT+ is where you'll find our deepest stories, exclusives, and investigations related to biopharma, policy and politics, the life sciences, and health tech.

Learn more